Journal
MOLECULAR ONCOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/1878-0261.13417
Keywords
epigenetics; G9a; HCC; Myc
Categories
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is a highly lethal cancer with high prevalence worldwide. In this study, we demonstrated the overexpression of histone methyltransferase G9a in HCC, particularly in Myc-driven liver tumors. The increased expression of G9a was associated with poor prognosis and lower survival rates in HCC patients. We also revealed the cooperative interaction between c-Myc and G9a in HCC, highlighting their role in gene repression and cancer development. Additionally, combination therapy targeting G9a and CDK9 showed promising efficacy in patient-derived models of Myc-driven HCC.
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the world. Histone-lysine N-methyltransferase EHMT2 (also known as G9a) is a histone methyltransferase frequently overexpressed in many cancer types, including HCC. We showed that Myc-driven liver tumours have a unique H3K9 methylation pattern with corresponding G9a overexpression. This phenomenon of increased G9a was further observed in our c-Myc-positive HCC patient-derived xenografts. More importantly, we showed that HCC patients with higher c-Myc and G9a expression levels portend a poorer survival with lower median survival months. We demonstrated that c-Myc interacts with G9a in HCC and cooperates to regulate c-Myc-dependent gene repression. In addition, G9a stabilises c-Myc to promote cancer development, contributing to the growth and invasive capacity in HCC. Furthermore, combination therapy between G9a and synthetic-lethal target of c-Myc, CDK9, demonstrates strong efficacy in patient-derived avatars of Myc-driven HCC. Our work suggests that targeting G9a could prove to be a potential therapeutic avenue for Myc-driven liver cancer. This will increase our understanding of the underlying epigenetic mechanisms of aggressive tumour initiation and lead to improved therapeutic and diagnostic options for Myc-driven hepatic tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available